Argus raised the firm’s price target on Elevance Health (ELV) to $465 from $450 and keeps a Buy rating on the shares. The company’s results calmed concerns raised by a competitor in the managed-care space about pressure from rising medical costs in the Medicare Advantage business, and Elevance remains on the path to achieve margin recovery for its commercial business, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health’s Strong Q1 2025 Performance and Diverse Revenue Streams Justify Buy Rating
- ‘Medicaid to the Rescue,’ Says Wall St. Analyst About Elevance Health (ELV) Stock
- Elevance Health’s Growth Potential Justifies Buy Rating Amid Sector Challenges
- Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook with Potential Upside
- Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves